CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia | ClinicLens

New England Journal of Medicine, Volume 395, Issue 6, Page 624-624, August 6, 2026.

Medical Literature · Updated 2026-08-10

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.